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Abstract  Hypertriglyceridemia  is  associated  with  a 
number  of  severe  diseases  such  as  acute  pancreatitis  and 
coronary  artery  disease.  In  severe  hypertriglyceridemia 
(SHTG,  triglycerides  > 1000  mg/dl),  rapid  lowering  of 
plasma  triglycerides  (TG)  has  to  be  achieved.  Treatment 
regimes  include  nutritional  intervention,  the  use  of  anti-




to be a  safe and useful  therapeutic  tool  in patients  suffer-
ing from SHTG. Apheretic treatment is able to remove the 
causative agent for pancreatic inflammation. Data suggests 
that  the  use  of  apheresis  should be performed  as  early  as 






Severe hypertriglyceridemia  (SHTG)  is well  known  to be 
associated with  severe  diseases  such  as  acute  pancreatitis 
and cardiovascular disease.
Concerning  the  role of  triglycerides  (TG)  in promoting 
cardiovascular disease,  there are still controversial discus-
sions more  than  60  years  after Moreton first  postulated  a 
relationship  between  them  [1].  However,  recent  data  on 
SHTG are likely to settle this debate by establishing a con-













postulated  by  Speck  [12]  in  1865,  the  topic  has  attracted 
many research efforts. Several mechanisms for the disease 
have been proposed,  including  the hydrolysis of TGs  for-
ming free fatty acids inducing inflammation, chylomicrons 
inducing  hyperviscosity  leading  to  ischemia,  and,  finally, 
genetic predisposition [13, 14]. In addition, cytokines seem 
to play a major role in acute pancreatitis including the sys-
temic  responses  [15],  yet  the  exact  pathophysiology  still 
remains unclear and is still controversially discussed.
It  is  generally  believed  that  TG  levels  of  > 1000  mg/




serum TG  levels  is  a  primary medical  goal  in  preventing 
serious harm to the patient suffering from SHTG.
The general treatment regimen for SHTG includes dietary 





























but  has  also  been  suggested  by  the American Society  for 
Apheresis (ASFA) Committee on Clinical Applications.
Causes of hypertriglyceridemia
The  causes  of  hypertriglyceridemia  may  be  categorized 








condition  is  probably  of  plurigenetic  origin with  a  strong 
environmental  and  lifestyle  impact  on  its  manifestation. 
Occasionally, a patient with ApoE2/E2 homozygosis (dys-































Insulin  treatment  is  often  considered  helpful  in  lowering 
SHTG, because insulin activates LPL leading to an accele-
ration of chylomicron degradation. As SHTG often presents 
in  poorly  controlled  diabetic  patients,  aggressive  insu-































The  beneficial  effect  of  plasmapheresis  is  believed  to 
be  due  to  a  rapid  decrease  in  TG  levels,  yet  removal  of 
excessive  proteases  from  the  plasma  and  replacement  of 





ventions). After  treatment,  the mean plasma TG and  total 
cholesterol concentrations were significantly reduced from 
1,929  and  510 mg/dl  to  762  and  227 mg/dl,  respectively. 
The removal of TG-rich lipoproteins by therapeutic plasma 







As  many  studies  suggest,  the  timing  of  the  apheretic 
treatment might be crucial  [29, 32, 33]. There are  several 




diagnosis. A TG  reduction  by  65–70% was  observed. All 
patients were  discharged  in  a  good  condition. Among  the 
subjects was  a  pregnant  patient with  SHTG-induced  pan-
creatitis, who gave birth to a healthy child later on.















































LPL  lipoprotein  lipase;  TG  triglycerides; FA  fatty  acids; FFA free  fatty  acid; VLDL  very  low  density  lipoproteins; HMG-CoA  hydroxy-
methylglutaryl-coenzyme-A; MCT medium-chain triglycerides; HTG hypertriglyceridemia

















Yeh et al. [31] 17 FFP and albumin Significant 
reduction
Chen et al. [32] 94 FFP and albumin n.a.
Gubensek et al. [34] 50 Albumin Significant 
reduction






tive  study. No benefit  concerning  the  rate of overall mor-
tality  and  complications  could  be  detected.  However,  as 
concluded  by  the  authors,  the  timing  of  apheresis  might 
exactly be the critical point in this study.
Technical  details  concerning  apheretic  treatment  are 
also  increasingly  under  investigation.  Till  date,  there  are 
two  small  studies  comparing  plasmapheresis  with  double 
membrane filtration in patients with SHTG [31, 40]. Both 









levels. Data  suggests  that  the  use  of  apheresis  in  patients 





Apheretic  treatment  is  indicated  in  medical  emergen-
cies such as hypertriglyceridemic pancreatitis if TG levels 
are  excessively  elevated  (TG  > 1000  mg/dl).  Apheretic 
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